Odyssey Therapeutics, Inc. (Ticker: ODTX US) is an American clinical-stage biopharmaceutical company focused on internally discovered small molecule and protein therapeutics for inflammatory and autoimmune diseases. Its lead program, OD-07656, is a RIPK2 inhibitor in Phase 2a development for ulcerative colitis, with additional preclinical programs targeting IRAK4 and TNFR2.

Odyssey plans to list on NASDAQ on May 8, 2026, following pricing on May 7, 2026. According to the published terms, the company is offering 13.24 million primary shares at a price range of $16.00 to $18.00 per share, raising approximately $225 million at the $17.00 midpoint. TPG may purchase up to an additional $25 million in a concurrent private placement. Estimated market capitalization is approximately $765 million. Net proceeds from the IPO are expected to go to the company, as the offering consists entirely of primary shares. Founded in 2021 by CEO Gary Glick, Odyssey is backed by a global syndicate of more than 30 investors. J.P. Morgan, TD Cowen and Cantor are acting as bookrunners.